---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-047227"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-10-15T20:05:33+00:00"
generated_at: "2026-10-15T20:07:13.935755+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences sets Dec. 1, 2026 note maturity in fifth amendment with Adjuvant

## Summary
- Fifth Amendment to the Oct. 14, 2020 Securities Purchase Agreement with Adjuvant Global Health Technology Fund signed Oct. 9, 2026
- Notes plus accrued interest now due in full on earliest of Dec. 1, 2026, a Change of Control elected by Adjuvant, or acceleration under Section 8
- Notes may not be prepaid before Dec. 1, 2026 without Adjuvant's prior written consent
- Section 7.1(f) affirmative covenant deleted in its entirety and replaced with '[Reserved]'
- Adjuvant represented it holds a majority of outstanding note balances, constituting the Requisite Purchasers under Section 10.8

## SEC filing metadata
- accession: 0001493152-26-047227
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-10-15T20:05:33+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/0001493152-26-047227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-047227
- JSON: https://secwatch.observer/filing/0001493152-26-047227.json
- Plain text: https://secwatch.observer/filing/0001493152-26-047227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.